ESMO21 & New Drugs (Cervical Ca Focus)
Sep 23, 2021•23 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Lots to discuss from ESMO 2021 to new drug approvals.
First, we discuss the updates in cervical cancer from ESMO (pembrolizumab with chemo) and the newly approved tisotumab-vedotin.
Then, we discuss another new agent, mobocertinib and its scary QT prolongation profile as well as cabo-confusion in thyroid cancer.
Finally, we discuss the potentially practice changing, but preliminary, data from ESMO in bladder cancer (VESPER) and HER2+ MBC (DESTINY-Breast03).
For the best experience, listen in Metacast app for iOS or Android